Synta Pharmaceuticals Corp. (NASDAQ:SNTA) reported financial results for the third quarter ended September 30, 2015 and provided an update on its business strategy.
Analysts are weighing in on the controversial drug giant Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Lexington biotech company Synta Pharmaceuticals Corp. (NASDAQ:SNTA), as shares of both companies fell …
Roth Capital analysts came out with bullish calls on the Cambridge biotech company Sarepta Therapeutics Inc (NASDAQ:SRPT) and Lexington biotech company Synta Pharmaceuticals Corp. (NASDAQ:SNTA), following recent meetings …
In a research report released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on shares of Synta Pharmaceuticals Corp. (NASDAQ:SNTA), with a $13 price …
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced the formation of anExpert Oncology Panel to provide guidance on research and development strategies for the Company’s portfolio of …
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced the appointment ofAlan C.
MLV analyst Arlinda Lee weighed in with a few insights on Synta Pharmaceuticals Corp. (NASDAQ:SNTA), after the company released its second-quarter results and provided update on its pipeline.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) reported financial results for the second quarter ended June 30, 2015 and provided a pipeline update.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) has been reiterated as a Buy at Cowen by research analyst Boris Peaker.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced that Phase 1 clinical results from three investigator-sponsored trials evaluating ganetespib combination therapy in ALK-positive lung cancer, platinum-resistant ovarian …